Active Lung Cancer Trials Across the START Newtwork
Active Lung Cancer Trials at START Mountain Region
Lung Cancer Referrals Since 2023
Lung Cancer Patients Enrolled Since 2023
START Research brings world-class expertise and one of the strongest early-phase lung cancer trial portfolios in the world. Our global team of specialists works at the forefront of innovation, helping to advance the newest targeted therapies, immunotherapies, and first-in-human treatments.
Through START’s integrated network of 15 global sites, patients and physicians gain fast, streamlined access to cutting-edge clinical trials—no matter where they are. With centralized support, rapid activation processes, and more than 100+ active lung cancer studies, START delivers consistency, speed, and exceptional care for our patients.
Meet START's
Lung Cancer Experts
Jose Maria Pacheco, MD
Clinical Investigator, START Mountain Region
Our Regional Expert
Your Regional Expert in Lung Cancer Research
Dr. Jose Pacheco brings extensive, world-class experience in phase I clinical trials and thoracic oncology. He has particular expertise in lung cancers, thymic tumors, mesothelioma, adrenal cancer, and NUT midline carcinomas.
Dr. Pacheco has led numerous clinical trials and contributed to FDA approvals for targeted therapies like trastuzumab deruxtecan and adagrasib. His research has been supported by the NIH and other sponsors, and he’s presented at major conferences including ASCO and the World Conference on Lung Cancer.
Get in Touch
Contact Us
Have a question about our lung cancer trials at START Mountain Region? Click below to contact Dr. Pacheco
Lung Cancer Trials
START Mountain Region's Lung Cancer Trial Spotlight
NCT06554795
Duality Bio DB-1419
- B7H3 and PD-L1 bispecific antibody drug conjugate with a topoisomerase 1 inhibitor payload
- Likely to be a highly effective option for previously treated small cell lung cancer patients with prior tarlatamab or for whom tarlatamab in not an option
NCT07038343
AVZO-1418
- This medication has received FDA breakthrough therapy designation for previously treated EGFR mutated non-small cell lung cancer
- EGFR and Her3 bispecific antibody drug conjugate with topoisomerase 1 inhibitor payload
NCT06242470
MGC026 in Participants with Advanced Solid Tumors
- B7H3 and PD-L1 bispecific antibody drug conjugate with a topoisomerase 1 inhibitor payload
- Likely to be a highly effective option for previously treated small cell lung cancer patients with prior tarlatamab or for whom tarlatamab in not an option
NCT07099898
GSK5764227 Alone and in Combinations with Platinum or Checkpoint Inhibitor
- This medication has received FDA breakthrough therapy designation for previously treated extensive stage small cell lung cancer
- B7H3 antibody drug conjugate with topoisomerase 1 inhibitor payload
- Likely to be highly effective option for previously treated small cell lung cancer patients with prior tarlatamab or for whom tarlatamab is not an option
Make a Patient Referral
Do you have a patient who may be a good fit for one of our lung cancer trial? Make a referral below.
View all active Lung Cancer trials available at START Mountain region
Patient Criteria for Featured Trials
START is always happy to evaluate any patient who may benefit from an early-phase trial. For the spotlighted studies below, we are especially seeking patients who align with the following criteria.
For trials related to small cell lung cancer
- No active or untreated brain metastases
- No prior antibody drug conjugate with a topoisomerase inhibitor payload
- Should be previously treated
For the EGFR positive non-small cell lung cancer trial
- No active or untreated brain metastases
- Should have received prior EGFR inhibitor and platinum based chemotherapy
- No prior ADC with topoisomerase 1 inhibitor payload (e.g., datopotamab deruxtecan)
